On April 28, Ruizhi Pharmaceutical (300149) announced its 2024 annual report. The company's operating income was 970 million yuan, a year-on-year decrease of 14.8%; the net profit attributable to the parent company changed from a loss of 908 million yuan in the same period last year to a loss of 226 million yuan, and the loss amount decreased; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 911 million yuan in the same period last year to a loss of 236 million yuan, and the loss amount decreased; the net operating cash flow was 168 million yuan, a year-on-year increase of 11.4%; EPS (fully diluted) was -0.4548 yuan.

In the fourth quarter, the company's operating income was 252 million yuan, a year-on-year decrease of 13.9%; the net profit attributable to the parent company changed from a loss of 867 million yuan in the same period last year to a loss of 165 million yuan, and the loss amount decreased; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 862 million yuan in the same period last year to a loss of 167 million yuan, and the loss amount decreased; EPS was -0.331 yuan.

As of the end of the fourth quarter, the company's total assets were 1.996 billion yuan, a decrease of 18.8% from the end of the previous year; the net assets attributable to the parent company were 1.214 billion yuan, a decrease of 16.9% from the end of the previous year.

It should be noted that the financial data of the previous year was restated due to changes in accounting standards, and the above calculations are based on data before restatement.

In its 2024 annual report, the company pointed out that due to the influence of various factors such as changes in market demand, the operating performance did not meet expectations, resulting in signs of impairment of goodwill. Therefore, the impairment amount of goodwill formed by the acquisition of subsidiaries was 139 million yuan. In order to cope with the current challenges, the company will further improve its service capabilities, gain a deeper understanding of customer needs, and increase market expansion efforts to improve performance.

In terms of business operations, the company's chemical business, pharmacodynamic business and macromolecule business were all affected by the market environment, with operating income of 256 million yuan, 547 million yuan and 158 million yuan respectively, all down year-on-year, with the chemical business seeing the largest decline of 21.71%. The company plans to respond to industry fluctuations and seek long-term stable development by continuously investing in new technology platform construction and strengthening policy research.

https://finance.eastmoney.com/a/202504293392235764.html